US Stock MarketDetailed Quotes
HOWL Werewolf Therapeutics
- 6.750
- +0.540+8.70%
Close Apr 26 16:00 ET
- 6.750
- 0.0000.00%
Post 19:51 ET
292.59MMarket Cap-6428P/E (TTM)
6.780High6.100Low82.15KVolume6.220Open6.210Pre Close544.88KTurnover0.35%Turnover RatioLossP/E (Static)43.35MShares8.19452wk High2.63P/B156.51MFloat Cap1.57452wk Low--Dividend TTM23.19MShs Float23.990Historical High--Div YieldTTM10.95%Amplitude1.390Historical Low6.632Avg Price1Lot Size
Werewolf Therapeutics Stock Forum
Sign in to post a comment
Watching! Lots of information coming before EO2Q!
$Werewolf Therapeutics(HOWL.US$ Upcoming Milestones! Most if not all data of some sort is to be released before end of Q2!
WTX-124:
•In the first half of 2024, Werewolf expects to present additional interim dose-escalation data from the monotherapy dose-escalation arm, nominate a recommended dose for expansion and initiate monotherapy dose expansion arms.
•Additionally, Werewolf continues to progress combination dose escalation cohorts of the Ph...
WTX-124:
•In the first half of 2024, Werewolf expects to present additional interim dose-escalation data from the monotherapy dose-escalation arm, nominate a recommended dose for expansion and initiate monotherapy dose expansion arms.
•Additionally, Werewolf continues to progress combination dose escalation cohorts of the Ph...
2
2
Despite Werewolf Therapeutics' stock surge, its modest P/S ratio is justified due to inconsistent revenue growth and forecasted contraction. The weak outlook could continue to impact the share price.
Dr. Atkins sees great potential in Werewolf Therapeutics' immunotherapies for cancer treatment. Werewolf Therapeutics' CEO appreciates Atkins' expertise as the company grows.
1
Werewolf Therapeutics' revenue performance is uncertain, and it's P/S ratio is low compared to the biotech industry due to potential shrink in revenues. Its low P/S ratio is justified given other companies' revenue growth forecasts, indicating no significant share price rise.
Nice!
$Werewolf Therapeutics(HOWL.US$ Werewolf Therapeutics Q3 2023 EPS $(0.23) Up From $(0.40) Revenue $5.897M Beats $1.592M Estimate
$Werewolf Therapeutics(HOWL.US$ 👀werewolf in action now with massive buying volume today 🤣 lets hope its not spam in for few small postion
I like pstv only
📈💥 Let's seize Friday! Yesterday we witnessed a ticker surge with a 44.24% LONG MOVE. Today's focus:
✅1️⃣ HOWL Long > 2.73 Short < 2.61
✅2️⃣ NVOS Long > 0.3300 Short < 0.3095
✅3️⃣ CYTO Long > 0.2035 Short < 0.1855
✅4️⃣ PSTV Long > 1.64 Short < 1.49
✅5️⃣ IFRX Long > 1.62 Short < 1.53
✅6️⃣ FUBO Long > 3.20 Short < 2.99
✅1️⃣ HOWL Long > 2.73 Short < 2.61
✅2️⃣ NVOS Long > 0.3300 Short < 0.3095
✅3️⃣ CYTO Long > 0.2035 Short < 0.1855
✅4️⃣ PSTV Long > 1.64 Short < 1.49
✅5️⃣ IFRX Long > 1.62 Short < 1.53
✅6️⃣ FUBO Long > 3.20 Short < 2.99
Update
$Werewolf Therapeutics(HOWL.US$ Werewolf Therapeutics Presents Preliminary Monotherapy Data From Phase 1/1b Clinical Trial Establishing Proof of Mechanism for WTX-124 At the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting
1
No comment yet
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
BelleWeather : I’ve also got this one on my watchlist:)
TrytosaveabitOP BelleWeather: Fantastic! I hope you’re having a great and restful weekend! Back to account building tomorrow! GL!